The Challenge of Scaling Up
Moderna has the most sought-after vaccine, due to easy storage, and they plan to produce between 500 million and 1 billion doses during 2021. The challenge will be scaling up production to meet the tremendous demand. This article from Forbes details Moderna’s challenge, a common one in our industry.
Moderna is speeding up its scale up by using messenger RNA (mRNA) technology. The article notes that unlike traditional vaccines, which use virus proteins that need to grown over weeks, mRNA molecules are less complex and are produced via a chemical process, making production quicker.
At ASG, we understand those kinds of nuances. Even on a smaller scale it’s important to make the right choices when it comes to scale up and commercialization in regulated industries. Learn more about what we do and how we help.